Page 20 - University Of Ja News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from University of ja. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In University Of Ja Today - Breaking & Trending Today

Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers

Propanc Biopharma Analyzes Pancreatic Proenzymes Vs T-Cell Therapy Targeting Solid Tumors Such as Pancreatic, Ovarian & Colorectal Cancers
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today analyzes pancreatic proenzymes versus T-Cell therapy when targeting solid tumors such as pancreatic, ovarian and colorectal cancers. The analysis is prepared by the Company’s Chief Executive Officer, Mr. James Nathanielsz, in collaboration with joint lead researcher, Professor Macarena Perán, from the University of Jaén, Granada, Spain.
“We are making significant inroads in the way we treat cancer today, but there is a genuine need to continually challenge ourselves to improve the standard of care for many cancer types,” said James Nathanielsz. “At Propanc, we share a vision to develop ....

James Nathanielsz , J Kenyond Tosh , John Beard , Exchange Commission , University Of Ja , Edinburgh University , Propanc Biopharma Inc , Company Registration Statement On Form , Company Mechanism Of Action , Propanc Biopharma , Chief Executive Officer , Professor Macarena Per , Professor John Beard , Cancer Stem Cell , Potent Anti Tumour Agents , Registration Statement , ஜான் தாடி , பரிமாற்றம் தரகு , பல்கலைக்கழகம் ஆஃப் ஜா , எடின்பர்க் பல்கலைக்கழகம் , நிறுவனம் பதிவு அறிக்கை ஆன் வடிவம் , நிறுவனம் பொறிமுறை ஆஃப் நடவடிக்கை , தலைமை நிர்வாகி அதிகாரி , ப்ரொஃபெஸர் மகறென ஒன்றுக்கு , ப்ரொஃபெஸர் ஜான் தாடி , புற்றுநோய் தண்டு செல் ,

Evidence of Oldest Gynaecological Treatment on Record, Performed in Ancient Egypt 4,000 Years Ago - HeritageDaily

Scientists from the Universities of Granada and Jaén are studying the physical evidence found in the mummified remains of a woman who suffered severe trauma to the pelvis in 1878–1797 BC, linking them to a medical treatment described in various Egyptian medical papyri of the time
During the Qubbet el-Hawa Project, led by the University of Jaén (UJA) in Aswan (Egypt), in which scientists from the University of Granada (UGR) are participating, researchers have found evidence of the oldest gynaecological treatment on record, performed on a woman who lived in Ancient Egypt some 4,000 years ago and died in 1878–1797 BC. ....

Upper Egypt , Egypt General , Qubbet El Hawa , Alejandro Jimenez , Miguel Botella , Spracheund Altertumskunde , University Of Ja , Spanish Ministry Of Science , Spanish Association Of Egyptology , University Of Granada , Hawa Project , Ancient Egypt , River Nile , Emeritus Professor , Professor Botella , Spanish Ministry , Spanish Association , Image Credit , மேல் எகிப்து , எகிப்து ஜநரல் , அலெஜாண்ட்ரா ஜிமெனெஸ் , மிகுவல் போடெல்லா , பல்கலைக்கழகம் ஆஃப் ஜா , ஸ்பானிஷ் அமைச்சகம் ஆஃப் அறிவியல் , பல்கலைக்கழகம் ஆஃப் க்ரெநாட , ஹவா ப்ராஜெக்ட் ,

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Provides Shareholder Update
MELBOURNE, Australia (BUSINESS WIRE)
Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today on the progress of the Company, recent developments and forecast for 2021, as the Company prepares for entering clinical development for its lead product candidate, PRP, for the treatment and prevention of metastatic cancer. PRP represents a novel therapeutic approach, targeting and eradicating cancer stem cells, but leaving healthy stem cells alone, making it less toxic compared to current standard treatment options, like chemotherapy and radiotherapy. PRP does not suppress the immune system, and therefore in a post pandemic world, can offer support to cancer sufferers who are at risk of infection. ....

Propanc Biopharma , Aitor Gonz , James Nathanielsz , Julian Kenyon , Exchange Commission , University Of Ja , Drug Discovery Program , Propanc Biopharma Inc , Company Registration Statement On Form , Peter Mac Center , Company Mechanism Of Action , Chief Executive , Good Manufacturing Practice , Product Candidate , Macarena Per , Registration Statement , ஜூலியன் கெந்யந் , பரிமாற்றம் தரகு , பல்கலைக்கழகம் ஆஃப் ஜா , மருந்து கண்டுபிடிப்பு ப்ரோக்ர்யாம் , நிறுவனம் பதிவு அறிக்கை ஆன் வடிவம் , பீட்டர் மேக் மையம் , நிறுவனம் பொறிமுறை ஆஃப் நடவடிக்கை , தலைமை நிர்வாகி , நல்ல உற்பத்தி ப்ர்யாக்டீஸ் , ப்ராடக்ட் வேட்பாளர் ,